Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pp65-shLAMP DC + GM-CSF
- Development stage
- Unknown
- Lead developer
- Immunomic Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intradermal, Subcutaneous
01
Overview
This is a combination immunotherapy consisting of an autologous dendritic cell (DC) vaccine pulsed with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 fused to lysosome-associated membrane protein (shLAMP), administered together with granulocyte-macrophage colony-stimulating factor (GM-CSF). The DCs are engineered ex vivo to express the CMV pp65 antigen targeted to lysosomes via shLAMP, enhancing antigen presentation on MHC-II and stimulating T-cell mediated immune responses against tumor cells expressing CMV antigens. GM-CSF acts as an adjuvant, promoting differentiation and activation of DCs and other immune cells at the vaccination site. This combination has been investigated primarily for glioblastoma multiforme (GBM), aiming to induce robust anti-tumor immunity in patients[2][3][6][8].
- Other names
- autologous CMV-pp65-shLAMP-1 mRNA loaded dendritic cell vaccine + GM-CSF
02
Targets
CSF2RA (Granulocyte-macrophage colony-stimulating factor receptor subunit alpha)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on pp65-shLAMP DC + GM-CSF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pp65-shLAMP DC + GM-CSF.